RPL17 and hepatocellular carcinoma: These findings support the efficacy of triple combination therapy integrating locoregional, immunotherapeutic, and antiangiogenic treatments in advanced hepatocellular carcinoma.Recent studies have demonstrated that transarterial infusion of PD-1 inhibitors is both safe and effective.